|
Sánchez-del-Campo L., Rodríguez-López J.N. Targeting the methionine cycle for melanoma therapy with 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin. International Journal of Cancer. 15 November 2008. 123:2446-2455. 10.1002/ijc.23813
AÑO: 2008; IF: 4.734
|
18729182
|
Navarro-Perán E., Cabezas-Herrera J., Sánchez-Del-Campo L., García-Cánovas F., Rodríguez-López J.N. The anti-inflammatory and anti-cancer properties of epigallocatechin-3- gallate are mediated by folate cycle disruption, adenosine release and NF-κB suppression. Inflammation Research. October 2008. 57:472-478. 10.1007/s00011-008-8013-x
AÑO: 2008; IF: 1.457
|
|
Sánchez-del-Campo L., Otón F., Tárraga A., Cabezas-Herrera J., Chazarra S., Rodríguez-López J.N. Synthesis and biological activity of a 3,4,5-trimethoxybenzoyl ester analogue of epicatechin-3-gallate. Journal of Medicinal Chemistry. 10 April 2008. 51:2018-2026. 10.1021/jm701346h
AÑO: 2008; IF: 4.898
|
|
Marti-Diaz R, Sanchez-Del-Campo L, Montenegro MF, Hernandez-Caselles T, Pinero-Madrona A, Cabezas-Herrera J, Rodriguez-Lopez JN. Ex vivo engineering of phagocytic signals in breast cancer cells for a whole tumor cell-based vaccine. BMC Cancer. 2025 Jul 1;25(1):1029. doi: 10.1186/s12885-025-14432-1. PubMed PMID: 40596971; PubMed Central PMCID: PMC12211345.
AÑO: 2025; IF: 3.4
|